• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺结节病的皮质类固醇治疗。II期疾病隔日和每日剂量的前瞻性评估。

Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease.

作者信息

Selroos O, Sellergren T L

出版信息

Scand J Respir Dis. 1979 Aug;60(4):215-21.

PMID:531541
Abstract

Thirty-nine sarcoidosis patients with pulmonary infiltrations (stage II) of less than 5 years duration and not treated earlier with corticosteroids were randomly allocated for treatment with methylprednisolone for 7 months or for observation without therapy. Every other treated patient was given the drugs daily and every other followed an alternate-day regimen. After 7 months the chest radiographic finding, the forced vital capacity and the diffusion capacity for carbon monoxide were superior in the treated group. There was no difference between the two drug regimens. After 24 and 48 months no statistically significant differences between the untreated and the treated groups were found.

摘要

39例病程少于5年且未接受过皮质类固醇治疗的肺部浸润(II期)结节病患者被随机分为两组,一组接受甲基强的松龙治疗7个月,另一组不接受治疗仅进行观察。每隔一位接受治疗的患者每日给药,其余患者采用隔日给药方案。7个月后,治疗组的胸部X线表现、用力肺活量和一氧化碳弥散量均优于未治疗组。两种给药方案之间无差异。24个月和48个月后,未治疗组和治疗组之间未发现统计学上的显著差异。

相似文献

1
Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease.肺结节病的皮质类固醇治疗。II期疾病隔日和每日剂量的前瞻性评估。
Scand J Respir Dis. 1979 Aug;60(4):215-21.
2
[Prognosis and indications of corticosteroid treatment of intrathoracic sarcoidosis--conclusions from a prospective study].[糖皮质激素治疗胸内结节病的预后及指征——一项前瞻性研究的结论]
Z Erkr Atmungsorgane. 1985;164(1):43-59.
3
Do chest radiographic findings reflect the clinical course of patients with sarcoidosis during corticosteroid withdrawal?胸部X线检查结果能否反映结节病患者在停用皮质类固醇期间的临床病程?
AJR Am J Roentgenol. 1990 Mar;154(3):481-5. doi: 10.2214/ajr.154.3.2106208.
4
Evidence that steroids alter the natural history of previously untreated progressive pulmonary sarcoidosis.有证据表明类固醇会改变先前未经治疗的进行性肺结节病的自然病程。
Sarcoidosis. 1986 Mar;3(1):40-6.
5
Daily vs alternate day prednisone therapy for stage II sarcoidosis.
Chest. 1985 Nov;88(5):687-90. doi: 10.1378/chest.88.5.687.
6
Two asymptomatic cases with sarcoidosis demonstrated sequential evolution from radiographic stage I to III within five years.
Hiroshima J Med Sci. 1999 Sep;48(3):101-3.
7
Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to corticosteroid therapy.肺结节病患者血清干扰素-γ水平升高及其与皮质类固醇治疗反应的关系。
Am Rev Respir Dis. 1991 Jan;143(1):53-60. doi: 10.1164/ajrccm/143.1.53.
8
The sequence of physiologic changes in pulmonary sarcoidosis: correlation with radiographic stages and response to therapy.
Mt Sinai J Med. 1977 Nov-Dec;44(6):852-65.
9
Sarcoidosis: a correlation of dyspnea with roentgenographic stage and pulmonary function changes.
Mayo Clin Proc. 1974 Oct;49(10):742-5.
10
Sarcoidosis: a review of cases seen at the University Hospital, Kuala Lumpur.
Singapore Med J. 1993 Apr;34(2):153-6.

引用本文的文献

1
Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review.肺结节病的免疫抑制治疗:一项实用的、基于证据的综述
J Clin Med. 2025 Sep 26;14(19):6828. doi: 10.3390/jcm14196828.
2
Clinical characteristics of patients with pulmonary sarcoidosis treated with systemic steroids in Japan.日本接受全身性激素治疗的结节病患者的临床特征
Front Med (Lausanne). 2025 May 30;12:1567334. doi: 10.3389/fmed.2025.1567334. eCollection 2025.
3
Glucocorticoid therapy in respiratory illness: bench to bedside.糖皮质激素在呼吸系统疾病中的治疗:从基础到临床。
J Investig Med. 2022 Dec;70(8):1662-1680. doi: 10.1136/jim-2021-002161. Epub 2022 Jun 28.
4
Clinical characteristics and outcomes of Korean patients with sarcoidosis.韩国结节病患者的临床特征和结局。
Sci Rep. 2021 Dec 8;11(1):23700. doi: 10.1038/s41598-021-03175-1.
5
Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP).间质性肺疾病的管理:印度胸科学会(ICS)和国家胸科医师学院(NCCP)的共识声明
Lung India. 2020 Jul-Aug;37(4):359-378. doi: 10.4103/lungindia.lungindia_275_20.
6
Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study.韩国的结节病流行率和发病率:一项全国性基于人群的研究。
Respir Res. 2018 Aug 28;19(1):158. doi: 10.1186/s12931-018-0871-3.
7
Treatment of Sarcoidosis.结节病的治疗。
Clin Rev Allergy Immunol. 2015 Aug;49(1):79-92. doi: 10.1007/s12016-015-8492-9.
8
Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.广谱抗分枝杆菌疗法对慢性肺结节病的影响。
Sarcoidosis Vasc Diffuse Lung Dis. 2013 Nov 25;30(3):201-11.
9
Corticosteroids for pulmonary sarcoidosis.用于治疗肺部结节病的皮质类固醇。
Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD001114. doi: 10.1002/14651858.CD001114.pub2.
10
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.英国胸科学会结节病研究:长期皮质类固醇治疗的效果
Thorax. 1996 Mar;51(3):238-47. doi: 10.1136/thx.51.3.238.